Interleukin-2 receptor subunit α

Target id: 1695

Nomenclature: Interleukin-2 receptor subunit α

Quaternary Structure: Complexes
Interleukin-2 receptor

Gene and Protein Information
Species	TM	AA	Chromosomal Location	Gene Symbol	Gene Name	Reference
Human	1	272	10p15.1	IL2RA	interleukin 2 receptor subunit alpha
Mouse	1	268	2 8.91 cM	Il2ra	interleukin 2 receptor, alpha chain
Rat	1	267	17q12.2	Il2ra	interleukin 2 receptor subunit alpha

Previous and Unofficial Names
CD25 \| TAC antigen \| IL2RAC \| IL-2R alpha chain \| Ly-43 \| interleukin 2 receptor

Database Links
Alphafold	P01589 (Hs), P01590 (Mm), P26897 (Rn)
ChEMBL Target	CHEMBL1778 (Hs), CHEMBL3287 (Mm)
DrugBank Target	P01589 (Hs)
Ensembl Gene	ENSG00000134460 (Hs), ENSMUSG00000026770 (Mm), ENSRNOG00000047647 (Rn)
Entrez Gene	3559 (Hs), 16184 (Mm), 25704 (Rn)
Human Protein Atlas	ENSG00000134460 (Hs)
KEGG Gene	hsa:3559 (Hs), mmu:16184 (Mm), rno:25704 (Rn)
OMIM	147730 (Hs)
Pharos	P01589 (Hs)
UniProtKB	P01589 (Hs), P01590 (Mm), P26897 (Rn)
Wikipedia	IL2RA (Hs)

Download all structure-activity data for this target as a CSV file go icon to follow link

Antibodies

Key to terms and symbols

Click column headers to sort

Antibody		Sp.	Action	Value	Parameter	Reference
daclizumab		Hs	Binding	>8.0	pK_d	1
⤷	pK_d >8.0 (K_d <1x10^-8 M) [1]
basiliximab		Hs	Binding	-	-
⤷

Immunopharmacology Comments
IL2RA is a ligand binding component of the IL-2R complex. This subunit is the molecular target of the approved biologics daclizumab (including daclizumab beta) and basiliximab. Another anti-CD25 mAb, inolimomab, has received orphan drug designation from the EMA, for the treatment of graft-versus-host disease. Phase 3 findings for this drug and indication are reported in [2], the major conclusion being that the primary end point for the trial was not met (no statistical difference between the inolimomab and normal standard of care arms of the study).

Immunopharmacology Comments

IL2RA is a ligand binding component of the IL-2R complex. This subunit is the molecular target of the approved biologics daclizumab (including daclizumab beta) and basiliximab. Another anti-CD25 mAb, inolimomab, has received orphan drug designation from the EMA, for the treatment of graft-versus-host disease. Phase 3 findings for this drug and indication are reported in [2], the major conclusion being that the primary end point for the trial was not met (no statistical difference between the inolimomab and normal standard of care arms of the study).

Immuno Process Associations

Immuno Process:

Inflammation

Immuno Process:

Immune regulation

Immuno Process:

Immune system development

Immuno Process:

Cytokine production & signalling

Immuno Process:

T cell (activation)

Immuno Process:

Chemotaxis & migration

Immuno Process:

Cellular signalling

References

Show »« Hide

1. Queen CL, Schneider WP, Selick HE. (1997) Genetic engineering; complementarity zones. Patent number: US5693761. Assignee: Protein Design Labs, Inc.. Priority date: 28/12/1988. Publication date: 02/12/1997.

2. Socié G, Vigouroux S, Yakoub-Agha I, Bay JO, Fürst S, Bilger K, Suarez F, Michallet M, Bron D, Gard P et al.. (2017) A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD. Blood, 129 (5): 643-649. [PMID:27899357]

How to cite this page

IL-2 receptor family: Interleukin-2 receptor subunit α. Last modified on 27/10/2017. Accessed on 15/10/2024. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetomalariapharmacology.org/GRAC/ObjectDisplayForward?objectId=1695.

Interleukin-2 receptor subunit α

Contents:

References

How to cite this page